Jazz Pharmaceuticals JAZZ De-recognition of finance lease liability on lease assignment / termination
De-recognition of finance lease liability on lease assignment / termination at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept jazz:DeRecognitionOfFinanceLeaseLiabilityOnLeaseAssignmentTermination.
The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's de-recognition of finance lease liability on lease assignment / termination.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's de-recognition of finance lease liability on lease assignment / termination?
- Jazz Pharmaceuticals (JAZZ) reported de-recognition of finance lease liability on lease assignment / termination of $255.75K in Q4 2025.
- What does de-recognition of finance lease liability on lease assignment / termination mean?
- The value of finance lease debt removed due to lease termination.
- How do you interpret de-recognition of finance lease liability on lease assignment / termination?
- Extinguishing finance lease liabilities reduces long-term debt burdens, potentially improving the company's leverage profile.
- How does de-recognition of finance lease liability on lease assignment / termination compare across companies?
- Standardized accounting for debt extinguishment via lease termination.